Liver cancer

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer

   Rochester, Minn.

   This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary liver transplant are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.

2. A Study of Predictors of Renal Insufficiency Following Orthotopic Liver Transplantation

   Rochester, Minn.

   The purpose of this study is to see if certain pre-transplant markers are able to predict how the kidney will respond after a liver transplant.

3. A Study Using TRC105 and Sorafenib to Treat Patients with Liver Cell Cancer

   Jacksonville, Fla.

   The purpose of this phase 1b/2 study is to evaluate a safe and tolerable recommended dose for TRC105 when added to standard dose sorafenib in patients with liver cell cancer, then to estimate the overall response rate.

4. Immunomodulation Following Thermal Ablation of Hepatocellular Carcinoma by Radiofrequency or Microwave Ablations

   Rochester, Minn.

   The goal of the study is to identify immune responses (immune cell activation and suppression) following local ablation of liver tumors.

5. Viral Therapy in Treating Patient with Liver Cancer

   Scottsdale/Phoenix, Ariz.

   The primary purpose of this study is to evaluate the safety of a viral agent called vesicular stomatitis virus for the use in patients with liver cancer. The study virus has a gene inserted into it which will allow for the production of interferon beta, which is a substance that will have the dual functions of restricting the spread of the virus to the tumor cells and not healthy liver cells and also to have some independent anti-cancer activity. Although the primary goal of this study is to evaluate the safety of delivery of this viral agent to people, patients may benefit clinically by having shrinkage or stabilization of their tumor or reduction in their cancer related symptoms (e.g. pain)

6. Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth by blocking blood flow to the tumor. Drugs used in chemotherapy, such as hypoxia-activated prodrug TH-302, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib tosylate together with hypoxia-activated prodrug TH-302 may kill more tumor cells. PURPOSE: This phase I/II trial studies the side effects and best dose of giving sorafenib tosylate together with hypoxia-activated prodrug TH-302 and to see how well they work in treating patients with advanced kidney cancer or liver cancer that cannot be removed by surgery.

7. A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib.

8. Tissue Collection for Patients with Cancers other than Hepatobilairy Cancers with Metastasis to the Liver

   Rochester, Minn.

   The goal of this study is to develop a resource (bank) of biospecimens (blood, tissue) from patients having cancers that metastasis to the liver. The purpose of the resource bank is to facilitate studies on the pathogenesis of cancers metastasizing to the liver and also in order to assess the ability of new tests to detect early cancer in the cohort of patients undergoing routine surveillance for cancer. The biospecimens will include cultures of tumor cells and tumor-associated non-malignant cells, as well as xenografts established from freshly isolated metastatic cancers in immunodeficient mice. We plan to administer a risk factor questionnaire to facilitate identification of risk factors for development of metastatic liver cancer. The study will also  determine survival of patients from time of diagnosis.

    

9. The Circulating Cell-free Genome Atlas Study

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.

10. Tissue and Blood Registry for Individuals with Liver and Biliary Tumors

    Jacksonville, Fla.

    This study will collect and store samples of tissue and blood for current and future research studies on Liver and Biliary Tumors.